Trifarotene: First Approval
- 98 Downloads
Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
- 3.US National Institue of Health. Lamellar ichthyosis. 2019. http://ghr.nlm.nih.gov/condition/lamellar-ichthyosis#diagnosis. Accessed 15 Oct 2019.
- 5.FDA. Novel drug approvals for 2019. 2019. http://www.fda.gov. Accessed 15 Oct 2019.
- 6.Galderma. Aklief® (Trifarotene): US Prescribing Information. 2019. http://www.galderma.com/. Accessed 2019 Oct 8.
- 7.Galderma. Galderma trifarotene development program meets key milestone for lamellar ichthyosis orphan disease [media release]. 2016. http://www.galderma.com/. Accessed 15 Oct 2019.
- 9.Thoreau E, Arlabosse J, Bouix-Peter C, et al. Structure-based design of trifarotene, a potent and selective RAR agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;128(101736-41).Google Scholar
- 11.Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2019. https://doi.org/10.1111/jdv.15794.CrossRefPubMedGoogle Scholar
- 12.Galderma (2019) Data on fileGoogle Scholar